All In Biotech

Drug Trial Radar · NCT00863707

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

A Phase 4, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Last checked: Nov 20, 2026Latest source record: May 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 511 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

511

Actual

Start

Apr 2009

Primary completion

Dec 2009

Study completion Dec 2009

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Mar 18, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to assess the safety and tolerance of regadenoson in subjects with renal impairment.

Conditions

  • Kidney Diseases
  • Coronary Artery Disease

Interventions

  • RegadenosonDrug

    IV

  • PlaceboDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subject With Serious Treatment Emergent Adverse Events (TEAE)Time frame: 24 hours post dose

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Anniston, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Bell Gardens, California

  • Site not named

    Fullerton, California

  • Site not named

    Garden Grove, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mission Viejo, California

  • Site not named

    Oakland, California

  • Site not named

    Roseville, California

  • Site not named

    Santa Ana, California

  • Site not named

    Newark, Delaware

  • Site not named

    Wilmington, Delaware

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Trinity, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Ellijay, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Auburn, Maine

  • Site not named

    Detroit, Michigan

  • Site not named

    Flint, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Ridgewood, New Jersey

  • Site not named

    Somerset, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Springfield Gardens, New York

  • Site not named

    Springfield, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Bend, Oregon

  • Site not named

    Duncansville, Pennsylvania

  • Site not named

    Indiana, Pennsylvania

  • Site not named

    Tyrone, Pennsylvania

  • Site not named

    Wyomissing, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Spartanburg, South Carolina

  • Site not named

    Knoxville, Tennessee

  • Site not named

    Houston, Texas

  • Site not named

    Houston, Texas

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.